SUVEN LIFESCIENCES 2018-19 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis
Mon, 22 Jul

SUVEN LIFESCIENCES has announced its results for the year ended March 2019. Let us have a look at the detailed performance review of the company during FY18-19.

SUVEN LIFESCIENCES Income Statement Analysis

  • Operating income during the year rose 6.1% on a year-on-year (YoY) basis.
  • The company's operating profit decreased by 19.1% YoY during the fiscal. Operating profit margins witnessed a fall and stood at 24.2% in FY19 as against 31.7% in FY18.
  • Depreciation charges increased by 3.9% and finance costs decreased by 18.6% YoY, respectively.
  • Other income grew by 4.1% YoY.
  • Net profit for the year declined by 29.7% YoY.
  • Net profit margins during the year declined from 19.1% in FY18 to 12.6% in FY19.

SUVEN LIFESCIENCES Income Statement 2018-19

No. of Mths Year Ending 12 Mar-18* 12 Mar-19* % Change
Net Sales Rs m 6,253 6,635 6.1%
Other income Rs m 233 242 4.1%
Total Revenues Rs m 6,485 6,877 6.0%
Gross profit Rs m 1,982 1,604 -19.1%
Depreciation Rs m 213 221 3.9%
Interest Rs m 46 38 -18.6%
Profit before tax Rs m 1,955 1,587 -18.8%
Tax Rs m 718 718 0.0%
Profit after tax Rs m 1,237 869 -29.7%
Gross profit margin % 31.7 24.2
Effective tax rate % 36.7 45.2
Net profit margin % 19.1 12.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



SUVEN LIFESCIENCES Balance Sheet Analysis

  • The company's current liabilities during FY19 stood at Rs 1 billion as compared to Rs 1 billion in FY18, thereby witnessing an increase of 22.6%.
  • Long-term debt down at Rs 18 million as compared to Rs 22 million during FY18, a fall of 19.8%.
  • Current assets rose 9% and stood at Rs 6 billion, while fixed assets rose 22% and stood at Rs 4 billion in FY19.
  • Overall, the total assets and liabilities for FY19 stood at Rs 10 billion as against Rs 9 billion during FY18, thereby witnessing a growth of 13%.

SUVEN LIFESCIENCES Balance Sheet as on March 2019

No. of Mths Year Ending 12 Mar-18* 12 Mar-19* % Change
Networth Rs m 7,674 8,310 8.3
 
Current Liabilities Rs m 1,216 1,490 22.6
Long-term Debt Rs m 22 18 -19.8
Total Liabilities Rs m 9,192 10,389 13.0
 
Current assets Rs m 5,696 6,232 9.4
Fixed Assets Rs m 3,325 4,043 21.6
Total Assets Rs m 9,192 10,389 13.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



SUVEN LIFESCIENCES Cash Flow Statement Analysis

  • SUVEN LIFESCIENCES's cash flow from operating activities (CFO) during FY19 stood at Rs 356 million on a YoY basis.
  • Cash flow from investing activities (CFI) during FY19 stood at Rs -279 million, an improvement of 4,467.2% on a YoY basis.
  • Cash flow from financial activities (CFF) during FY19 stood at Rs -225 million, an improvement of 57% on a YoY basis.
  • Overall, net cash flows for the company during FY19 stood at Rs -148 million from the Rs 173 million net cash flows seen during FY18.

SUVEN LIFESCIENCES Cash Flow Statement 2018-19

Particulars No. of months 12 12 % Change
Year Ending Mar-18 Mar-19
Cash Flow from Operating Activities Rs m 699 356 -49.2%
Cash Flow from Investing Activities Rs m -6 -279 -
Cash Flow from Financing Activities Rs m -521 -225 -
Net Cash Flow Rs m 173 -148 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for SUVEN LIFESCIENCES

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 6.8, an decline from the EPS of Rs 9.7 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 239.9, stands at 18.7 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 3.9 times, while the price to sales ratio stands at 4.9 times.
  • The company's price to cash flow (P/CF) ratio stood at 25.7 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-18* 12 Mar-19*
Sales per share (Unadj.) Rs 49.1 52.1
TTM Earnings per share Rs 9.7 6.8
Diluted earnings per share Rs 10.6 7.4
Price to Cash Flow x 21.1 25.7
TTM P/E ratio x 20.3 18.7
Price / Book Value ratio x 3.4 3.9
Market Cap Rs m 30,534 28,028
Dividends per share (Unadj.) Rs 1.5 1.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for SUVEN LIFESCIENCES

  • Solvency Ratios
  • Current Ratio: The company's current ratio deteriorated and stood at 4.2x during FY19, from 4.7x during FY18. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 43.1x during FY19, from 43.2x during FY18. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 10.5% during FY19, from 16.1% during FY19. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 19.5% during FY19, from 26.0% during FY18. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 8.7% during FY19, from 14.0% during FY18. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-18* 12 Mar-19*
Current ratio x 4.7 4.2
Debtors’ Days Days 36 83
Interest coverage x 43.2 43.1
Debt to equity ratio x 0.0 0.0
Return on assets % 14.0 8.7
Return on equity % 16.1 10.5
Return on capital employed % 26.0 19.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how SUVEN LIFESCIENCES has performed over the last 5 years, please visit here.

SUVEN LIFESCIENCES Share Price Performance

Over the last one year, SUVEN LIFESCIENCES share price has moved up from Rs 223.8 to Rs 239.9, registering a gain of Rs 16.2 or around 7.2%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,822.0 (up 0.4%). Over the last one year it has moved down from 13,661.3 to 12,822.0, a loss of 839 points (down 6.1%).

Overall, the S&P BSE SENSEX is up 4.6% over the year.

(To know more, check out historical annual results for SUVEN LIFESCIENCES and quarterly results for SUVEN LIFESCIENCES)

Equitymaster requests your view! Post a comment on "SUVEN LIFESCIENCES 2018-19 Annual Report Analysis". Click here!

  

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

3 Stocks to Ride the Big Rebound in Smallcaps(Profit Hunter)

Aug 11, 2020

The rebound ratio suggests that smallcaps are set for big gains but this time it will be limited to a few stocks. Make sure you choose wisely.

Governance: for the country and your portfolio.(The Honest Truth)

Aug 14, 2020

Ajit Dayal on the need of socially responsible governance.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - ADCOCK INGRAM COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS